IL106463A - Arginine L Monomethyl GN Pure Solid Hydrochloride Preparation and Pharmaceutical Preparations Containing Them - Google Patents
Arginine L Monomethyl GN Pure Solid Hydrochloride Preparation and Pharmaceutical Preparations Containing ThemInfo
- Publication number
- IL106463A IL106463A IL10646393A IL10646393A IL106463A IL 106463 A IL106463 A IL 106463A IL 10646393 A IL10646393 A IL 10646393A IL 10646393 A IL10646393 A IL 10646393A IL 106463 A IL106463 A IL 106463A
- Authority
- IL
- Israel
- Prior art keywords
- monomethyl
- arginine
- hydrochloride
- arginine hydrochloride
- salt
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- QYGXVJHXZUSLQC-JEDNCBNOSA-N (2s)-2-amino-5-[(n'-methylcarbamimidoyl)amino]pentanoic acid;hydron;chloride Chemical compound Cl.CN=C(N)NCCC[C@H](N)C(O)=O QYGXVJHXZUSLQC-JEDNCBNOSA-N 0.000 title claims abstract 8
- 239000007787 solid Substances 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 40
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 claims description 26
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000010899 nucleation Methods 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000000155 melt Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 239000004480 active ingredient Substances 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000220479 Acacia Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229960003589 arginine hydrochloride Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- UDUMWDDMSHXGGQ-UHFFFAOYSA-N [amino(methylsulfanyl)methylidene]-methylazanium;iodide Chemical compound I.CSC(N)=NC UDUMWDDMSHXGGQ-UHFFFAOYSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- IKPNWIGTWUZCKM-JEDNCBNOSA-N acetic acid;(2s)-2-amino-5-[(n'-methylcarbamimidoyl)amino]pentanoic acid Chemical compound CC(O)=O.CN=C(N)NCCC[C@H](N)C(O)=O IKPNWIGTWUZCKM-JEDNCBNOSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- FCQJEPASRCXVCB-UHFFFAOYSA-L flavianate Chemical class C1=C(S([O-])(=O)=O)C=C2C([O-])=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FCQJEPASRCXVCB-UHFFFAOYSA-L 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229960003244 ornithine hydrochloride Drugs 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929215816A GB9215816D0 (en) | 1992-07-24 | 1992-07-24 | Arginine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL106463A0 IL106463A0 (en) | 1993-11-15 |
| IL106463A true IL106463A (en) | 1998-08-16 |
Family
ID=10719277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10646393A IL106463A (en) | 1992-07-24 | 1993-07-23 | Arginine L Monomethyl GN Pure Solid Hydrochloride Preparation and Pharmaceutical Preparations Containing Them |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0651741B1 (de) |
| JP (1) | JP2878844B2 (de) |
| KR (1) | KR950702528A (de) |
| CN (1) | CN1087624A (de) |
| AT (1) | ATE148451T1 (de) |
| CA (1) | CA2140852A1 (de) |
| CY (1) | CY2085B1 (de) |
| CZ (1) | CZ8095A3 (de) |
| DE (1) | DE69307894T2 (de) |
| DK (1) | DK0651741T3 (de) |
| ES (1) | ES2098051T3 (de) |
| GB (1) | GB9215816D0 (de) |
| GR (1) | GR3022773T3 (de) |
| HU (1) | HU210876A9 (de) |
| IL (1) | IL106463A (de) |
| MX (1) | MX9304466A (de) |
| NO (1) | NO302360B1 (de) |
| NZ (1) | NZ254865A (de) |
| PL (1) | PL307238A1 (de) |
| RU (1) | RU95105249A (de) |
| SG (1) | SG46425A1 (de) |
| SK (1) | SK8295A3 (de) |
| WO (1) | WO1994002453A1 (de) |
| ZA (1) | ZA935348B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424447A (en) * | 1993-07-07 | 1995-06-13 | The Medical College Of Wisconsin Research Foundation, Inc. | Heme binding compounds and use thereof |
| GB9603522D0 (en) * | 1996-02-20 | 1996-04-17 | Wellcome Found | Chemical process |
| AU2004207720A1 (en) * | 2003-01-31 | 2004-08-12 | Teijin Pharma Limited | Crystal of (23S)-1alpha-hydroxy-27-nor-25-methylenevitamin D3-26,23-lactone and process for producing the same |
| CN1724514B (zh) * | 2004-07-19 | 2010-06-09 | 上海依福瑞实业有限公司 | 一种l－高精氨酸盐酸盐的制备方法 |
| EP2020998A4 (de) * | 2006-05-23 | 2010-07-21 | Univ Utah Res Found | Zusammensetzungen und verfahren zur hemmung der endothelialen stickoxid-synthase-aktivität |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028627A (en) * | 1989-09-13 | 1991-07-02 | Cornell Research Foundation, Inc. | Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
-
1992
- 1992-07-24 GB GB929215816A patent/GB9215816D0/en active Pending
-
1993
- 1993-07-23 JP JP6504312A patent/JP2878844B2/ja not_active Expired - Lifetime
- 1993-07-23 DK DK93917905.7T patent/DK0651741T3/da active
- 1993-07-23 RU RU95105249/04A patent/RU95105249A/ru unknown
- 1993-07-23 MX MX9304466A patent/MX9304466A/es not_active IP Right Cessation
- 1993-07-23 ZA ZA935348A patent/ZA935348B/xx unknown
- 1993-07-23 WO PCT/GB1993/001563 patent/WO1994002453A1/en not_active Ceased
- 1993-07-23 SG SG1996004597A patent/SG46425A1/en unknown
- 1993-07-23 KR KR1019950700192A patent/KR950702528A/ko not_active Abandoned
- 1993-07-23 CZ CZ9580A patent/CZ8095A3/cs unknown
- 1993-07-23 ES ES93917905T patent/ES2098051T3/es not_active Expired - Lifetime
- 1993-07-23 CN CN93109375A patent/CN1087624A/zh active Pending
- 1993-07-23 EP EP93917905A patent/EP0651741B1/de not_active Expired - Lifetime
- 1993-07-23 CA CA002140852A patent/CA2140852A1/en not_active Abandoned
- 1993-07-23 AT AT93917905T patent/ATE148451T1/de not_active IP Right Cessation
- 1993-07-23 PL PL93307238A patent/PL307238A1/xx unknown
- 1993-07-23 DE DE69307894T patent/DE69307894T2/de not_active Expired - Fee Related
- 1993-07-23 IL IL10646393A patent/IL106463A/en not_active IP Right Cessation
- 1993-07-23 SK SK82-95A patent/SK8295A3/sk unknown
- 1993-07-23 NZ NZ254865A patent/NZ254865A/en unknown
-
1995
- 1995-01-23 NO NO950248A patent/NO302360B1/no unknown
- 1995-06-02 HU HU95P/P00152P patent/HU210876A9/hu unknown
-
1997
- 1997-03-07 GR GR970400457T patent/GR3022773T3/el unknown
-
1999
- 1999-03-05 CY CY9902085A patent/CY2085B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU669557B2 (en) | 1996-06-13 |
| NO950248L (no) | 1995-01-23 |
| DE69307894D1 (de) | 1997-03-13 |
| AU4715793A (en) | 1994-02-14 |
| RU95105249A (ru) | 1996-10-27 |
| ATE148451T1 (de) | 1997-02-15 |
| GB9215816D0 (en) | 1992-09-09 |
| KR950702528A (ko) | 1995-07-29 |
| CA2140852A1 (en) | 1994-02-03 |
| MX9304466A (es) | 1994-04-29 |
| NO302360B1 (no) | 1998-02-23 |
| ES2098051T3 (es) | 1997-04-16 |
| JP2878844B2 (ja) | 1999-04-05 |
| SG46425A1 (en) | 1998-02-20 |
| WO1994002453A1 (en) | 1994-02-03 |
| DE69307894T2 (de) | 1997-06-12 |
| GR3022773T3 (en) | 1997-06-30 |
| CY2085B1 (en) | 1999-03-05 |
| CN1087624A (zh) | 1994-06-08 |
| NO950248D0 (no) | 1995-01-23 |
| HU210876A9 (en) | 1995-09-28 |
| EP0651741B1 (de) | 1997-01-29 |
| JPH07509239A (ja) | 1995-10-12 |
| IL106463A0 (en) | 1993-11-15 |
| SK8295A3 (en) | 1995-07-11 |
| NZ254865A (en) | 1996-10-28 |
| EP0651741A1 (de) | 1995-05-10 |
| PL307238A1 (en) | 1995-05-15 |
| DK0651741T3 (da) | 1997-05-12 |
| CZ8095A3 (en) | 1995-10-18 |
| ZA935348B (en) | 1995-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101612642B1 (ko) | 테노포비어 알라펜아미드 헤미푸마레이트 | |
| US4942166A (en) | Crystalline purine compounds | |
| JP3726291B2 (ja) | 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法 | |
| AU739953B2 (en) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | |
| EP0651741B1 (de) | Ng-monomethyl-l-arginin-hydrochlorid-derivate und verfahren zu deren herstellung | |
| EP0361831B1 (de) | Virushemmende Nukleosidmischung | |
| US5856565A (en) | Ng-monomethyl-l-argine hydrochloride derivatives and their use in the treatment of septic shock | |
| AU669557C (en) | Ng-monomethyl-L-arginine hydrochloride derivatives and their use in the treatment of septic shock | |
| US4914222A (en) | Crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters and process | |
| AU767334B2 (en) | Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions | |
| US7429679B2 (en) | Sulphonic acid salt of sibutramine | |
| HU206628B (en) | Process for producing antiviral, watersoluble, stabile, christalline salts of 2',3'-dideoxyinozine-monohydate, 2,'3'-2'-fluoro-inozine-hemihydrate and pharmaceutical compositions containing them | |
| US3253990A (en) | N-methyl glucammonium salicylate and uses therefor | |
| EP0139983B1 (de) | Kristallisierte Salze von L oder (S)-3-(3,4-Dihydroxyphenyl)-2-methylalanin-Estern und Verfahren | |
| KR920006420B1 (ko) | 광학활성이 있는 류코보린칼슘염의 제조방법 | |
| JP4693236B2 (ja) | １−メチル−５−ｐ−トルオイルピロール−２−アセトアミド酢酸グアイアシルエステル（ＭＥＤ１５）の新規多形結晶 | |
| AU769660B2 (en) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | |
| MXPA99010373A (en) | Carbocyclic nucleoside hemisulfate and its use in treating viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| RH | Patent void |